What is he best known for?
The fields of study he is best known for:
- Cancer
- Immune system
- Internal medicine
His scientific interests lie mostly in Immunology, FOXP3, Antigen, Immune system and IL-2 receptor.
The study of Immunology is intertwined with the study of Cytotoxic T cell in a number of ways.
His FOXP3 research incorporates themes from Cancer research, Bacterial antigen and Immunotherapy.
His studies deal with areas such as Cancer and Antibody as well as Antigen.
His Immune system research focuses on Monoclonal antibody and how it relates to Peripheral blood mononuclear cell.
His study in IL-2 receptor is interdisciplinary in nature, drawing from both Interleukin 21, CD8 and T lymphocyte.
His most cited work include:
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer (1739 citations)
- Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota (1603 citations)
- Regulatory T cells in tumor immunity (694 citations)
What are the main themes of his work throughout his whole career to date?
Hiroyoshi Nishikawa spends much of his time researching Immunology, Cancer research, Immune system, Antigen and Internal medicine.
His Immunology study integrates concerns from other disciplines, such as Cytotoxic T cell and Cancer.
His work carried out in the field of Cytotoxic T cell brings together such families of science as T cell and Molecular biology.
His Cancer research study incorporates themes from Tumor microenvironment, Blockade and CD8, Tumor-infiltrating lymphocytes.
The Immune system study combines topics in areas such as Peripheral blood mononuclear cell and Monoclonal antibody.
His biological study spans a wide range of topics, including Antibody, Virology, Tumor antigen and NY-ESO-1.
He most often published in these fields:
- Immunology (43.52%)
- Cancer research (31.48%)
- Immune system (28.24%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (31.48%)
- Internal medicine (23.61%)
- CD8 (22.69%)
In recent papers he was focusing on the following fields of study:
Hiroyoshi Nishikawa mainly investigates Cancer research, Internal medicine, CD8, Oncology and Immune system.
Hiroyoshi Nishikawa combines subjects such as Tumor microenvironment, Cancer, Blockade and Cytotoxic T cell with his study of Cancer research.
His work investigates the relationship between Internal medicine and topics such as Gastroenterology that intersect with problems in Monoclonal.
His CD8 study is associated with Antigen.
His study in FOXP3, Cancer immunotherapy and Immunotherapy falls under the purview of Immune system.
FOXP3 connects with themes related to Cell type in his study.
Between 2018 and 2021, his most popular works were:
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy (226 citations)
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer (209 citations)
- Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? (109 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Immune system
- Internal medicine
Hiroyoshi Nishikawa spends much of his time researching Cancer research, Immune system, CD8, Tumor microenvironment and Internal medicine.
His Cancer research research integrates issues from Immune checkpoint, Immunotherapy, Immunohistochemistry, Cytotoxic T cell and Effector.
His research related to Cancer immunotherapy and FOXP3 might be considered part of Immune system.
His FOXP3 study combines topics from a wide range of disciplines, such as Cell type, Immune tolerance, Antibody-dependent cell-mediated cytotoxicity and Immunosurveillance.
His CD8 study combines topics in areas such as T cell and Blockade.
His Internal medicine research incorporates elements of Gastroenterology and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
